KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Capital Expenditures (2016 - 2026)

Medtronic's Capital Expenditures history spans 13 years, with the latest figure at $444.0 million for Q1 2026.

  • For Q1 2026, Capital Expenditures fell 6.72% year-over-year to $444.0 million; the TTM value through Jan 2026 reached $1.9 billion, up 2.68%, while the annual FY2025 figure was $1.9 billion, 17.14% up from the prior year.
  • Capital Expenditures for Q1 2026 was $444.0 million at Medtronic, down from $468.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $520.0 million in Q3 2024 and bottomed at $323.0 million in Q4 2022.
  • The 5-year median for Capital Expenditures is $426.0 million (2022), against an average of $414.1 million.
  • The largest annual shift saw Capital Expenditures decreased 16.9% in 2023 before it soared 46.89% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $323.0 million in 2022, then surged by 42.72% to $461.0 million in 2023, then fell by 12.36% to $404.0 million in 2024, then increased by 15.84% to $468.0 million in 2025, then fell by 5.13% to $444.0 million in 2026.
  • Per Business Quant, the three most recent readings for MDT's Capital Expenditures are $444.0 million (Q1 2026), $468.0 million (Q4 2025), and $504.0 million (Q3 2025).